NOVOCURE LTD (NVCR)
Health Care · medical devices - oncology · NASDAQ
Novocure is an oncology company utilizing proprietary Tumor Treating Fields (TTFields) to disrupt cancer cell division through wearable, non-invasive electric field therapy.
What NOVOCURE LTD does
Novocure is an oncology company that develops and commercializes Tumor Treating Fields (TTFields), a non-invasive cancer therapy that uses electric fields to disrupt solid tumor cell division. The company's primary focus is the treatment of aggressive solid tumors, such as glioblastoma (GBM). Its technology is delivered through wearable devices that patients use in their daily lives.
Themes: oncology, medical devices, cancer treatment innovation, bioelectronics
Fundamentals
- Price$14.22 as of 2026-10-08 close
- Market cap$1.7B as of 2026-07-17 (share count; price 2026-10-08)
- 1-year return-0.9% 2025-10-08 close $14.35 → 2026-10-08 close $14.22
- P/En/a negative earnings
- Net margin-20.8% FY2025, SEC XBRL
- Gross margin+74.5% FY2025, SEC XBRL
- ROE-40.0% FY2025, SEC XBRL
- Debt / equity0.58 as of 2026-09-03
- Revenue growth (YoY)+10.9% as of 2026-09-03
- Revenue CAGR (3y)+6.8% SEC XBRL
- Beta1.31 as of 2026-09-03
- Last reported earnings2026-07-23 SEC EDGAR Form 8-K (Item 2.02)
How NVCR compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross margintop 25% 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
NVCR is not currently in any published Top 10 list. Its scores are below.
Top 10 score
37.0 #1292 of 1,421 scored · #141 of 158 in Health Care
Trend 72nd (trading above its 200-day average) and growth 54th (revenue growth year over year 11%, 3-year revenue CAGR 6.8%); weakest is profitability (6th, return on equity -40%, operating margin -23.5%).
Scores as of 4 Sep 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4. NVCR was not in the scored universe at the latest run on 8 Oct 2026, so these scores are its last ones.
How NOVOCURE LTD looks technically
NOVOCURE LTD (NVCR) is trading 3.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 105 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 30, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, its first since 2026-06-23, breaking below its recent trading range. It is 33.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 3.4% below its 200-day average, the long-term trend line — a long-term downtrend | -3.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $16.51 | $16.51 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $14.71 | $14.71 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 16.99. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 105 trading days ago — a "golden cross", a bullish long-term signal | 105 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend | 19.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 30, neither overbought (above 70) nor oversold (below 30) | 30.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($13.82 to $16.87) — its "stochastic" reading is 13 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 13.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 25 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $21.36 | $21.36 |
|---|---|---|
| From the 52-week high | it is 33.4% below its 52-week high (its highest price of the past year) | -33.4% |
| Above the 52-week low | it is 44.8% above its 52-week low (its lowest price of the past year) | +44.8% |
| Below the 52-week high | it is 33.4% below its highest point of the past year | 33.4% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-06-23, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-06-23, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $232.74 (set on 2021-06-24) | $232.74 |
| Given back of the 52-week move | over the past year its closes ranged ($10.03 to $19.99), and it has given back a bit over half of its rise from last year’s low — 58% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $13.52 to $13.83. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 57.9% |
| From the all-time high | it is 93.9% below its all-time high | -93.9% |
| Nearest price level | it is sitting right on a resistance level at $14.26 — a price it turned at twice since 2025-10-30, most recently on 2026-01-22. Since 2024-10-08 it has 5 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.3% |
| All-time low | its lowest closing price on record is $5.95 (set on 2016-10-31) | $5.95 |
| Above the all-time low | it is 139.0% above its all-time low | +139.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 79% of it) | 21st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7399 between its high and its low — about 5.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7399 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $14.46 and $17.21 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $14.46 – $15.83 – $17.21 |
| Typical daily range (% of price) | its price moves about 5.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.2% |
| Stretch from the 200-day average | it is trading 0.7 daily ranges below its 200-day average price (3.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.67× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
|---|---|---|
| Since a bearish engulfing | 4 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 4 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.5% |
|---|---|---|
| Gap filled | a 2.0% gap up opened on 2026-10-02 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -6.45% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 16.6 percentage points (the stock lost 15.6% while the market gained 1.0%) | -16.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 22.0 percentage points (the stock lost 18.1% while the market gained 3.8%) | -22.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 17.3 percentage points (the stock gained 34.8% while the market gained 17.5%) | +17.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 15.9 percentage points (the stock lost 0.9% while the market gained 15.0%) | -15.9% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 17% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 2.2% of the share price. | -16.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $14.85 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -4.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 16% below the average price paid since it last reported on 2026-07-23 (its 10-Q), so the typical buyer over that stretch is under water. That average is $16.83 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | -15.5% |
Symmetrical triangle, either side — broke out · the lower entry $15.46 · 54 sessions in
Price levels it has turned at before
NVCR last closed at $14.22 on 2026-10-08. Since 2024-10-08 it has turned at 5 prices below its last close and 10 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $14.26 | Resistance | 0.3% above the last close | turned there twice · 2025-10-30 to 2026-01-22 |
| $13.96 | Support | 1.9% below the last close | turned there twice · 2025-12-11 to 2025-12-22 |
| $14.84 | Resistance | 4.4% above the last close | turned there five times · 2025-04-09 to 2026-07-31 |
| $13.45 | Support | 5.4% below the last close | turned there twice · 2025-09-23 to 2026-06-23 |
| $15.19 | Resistance | 6.8% above the last close | turned there five times · 2024-11-01 to 2026-09-10 |
| $12.85 | Support | 9.6% below the last close | turned there four times · 2025-10-14 to 2026-01-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $16.99.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $11.34 and $13.50 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $16.99.
This reading has stood for 11 trading days, since 2026-09-24.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) · beating the market · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$27.14 range $17.00 – $52.00; median $25.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NVCR
- Consensus EPS estimate-$0.2449 next reporting period, as of 2026-10-04
- Estimate change, 30 days$0.00 from -$0.2449, on 2026-08-30, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of net losses and accumulated deficit.","Substantial reliance on the commercial success of TTFields, particularly for glioblastoma.","Regulatory and clinical trial risks associated with ongoing and future cancer treatment research."]
What changed in the latest 10-Q
AI-assisted comparison of NVCR's 10-Q filed 2026-04-30 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-04-30) includes Optune Pax as a key priority product alongside Optune Gio and Optune Lua in the Overview section.
- Newer filing (2026-04-30) states Optune Pax is approved by FDA under PMA pathway for locally advanced pancreatic cancer concurrent with gemcitabine and nab-paclitaxel, with regulatory applications submitted to EU and Japan.
- Newer filing (2026-04-30) announces approval of a national reimbursement coverage policy in Japan for Optune Lua for treatment of NSCLC in March.
- Newer filing (2026-04-30) reports Phase 2 PANOVA-4 clinical trial results announced in March for metastatic pancreatic cancer with TTFields therapy combined with atezolizumab, gemcitabine and nab-paclitaxel, achieving 74% disease control rate versus 48% historical control.
- Newer filing (2026-04-30) mentions Phase 3 TRIDENT and KEYNOTE D58 trials in GBM and Phase 3 LUNAR-2 trial in NSCLC as ongoing clinical trials.
- Newer filing (2026-04-30) references submission of final PMA module in December 2025 for brain metastases from NSCLC approval under brand name Optune Mya.
- Removed:
- Older filing (2025-10-30) describes TTFields mechanism as killing cancer cells 'via a variety of mechanisms'; newer filing (2026-04-30) removes this mechanism description detail.
- Older filing (2025-10-30) includes statement about advancing Products 'with the intention to extend survival and maintain quality of life for patients'; this statement is removed in newer filing (2026-04-30).
- Older filing (2025-10-30) references 2024 10-K for critical accounting policies; newer filing (2026-04-30) references 2025 10-K.
- Older filing (2025-10-30) describes Optune Lua approval in Japan as 'received regulatory approval'; newer filing (2026-04-30) uses simplified language 'received regulatory approval in Japan'.
- Older filing (2025-10-30) includes August announcement of TTFields therapy coverage for newly diagnosed GBM in Spain; this is removed in newer filing (2026-04-30).
- Older filing (2025-10-30) contains detailed PANOVA-3 trial results (May presentation, July quality of life data, May publication, August PMA filing); newer filing (2026-04-30) removes all PANOVA-3 discussion and replaces with PANOVA-4 results.
- Older filing (2025-10-30) reports specific METIS trial results including risk reduction of 28% (HR 0.72, p=0.044) and median time to intracranial progression of 15.0 vs 7.5 months with detailed progression rates; newer filing (2026-04-30) provides only summary of METIS meeting primary endpoint without specific numerical results.
- Older filing (2025-10-30) discusses modular PMA shell approval and filing status of first two of three modules with FDA questions pending; newer filing (2026-04-30) reports final module submitted in December 2025.
- Reworded:
- Older filing (2025-10-30) states 'we market Optune Gio and Optune Lua in multiple countries'; newer filing (2026-04-30) states 'We market our Products in multiple countries' with Optune Pax now included as a Product.
- Older filing (2025-10-30) states 'We are actively evaluating opportunities to expand our international footprint'; newer filing (2026-04-30) states 'We are actively evaluating opportunities to expand access to Optune Gio, Optune Lua and Optune Pax in additional international markets.'
- Older filing (2025-10-30) states 'We are actively pursuing coverage policies with payers to expand access to Optune Lua for patients with NSCLC and MPM'; newer filing (2026-04-30) expands to 'We are actively pursuing coverage policies with payers to expand access to Optune Lua and Optune Pax'.
- Older filing (2025-10-30) references 'Optune Lua for the treatment of metastatic non-small cell lung cancer'; newer filing (2026-04-30) uses abbreviation 'metastatic NSCLC' consistently.
- Older filing (2025-10-30) states 'We have also received CE certification in the EU'; newer filing (2026-04-30) states 'We have also have a CE certificate in the EU'.
- Notes:
- Text appears truncated at end of both filings, potentially affecting completeness of comparison.
- Date references in Overview section differ: older filing references 2025 events (May, July, August, September 2025) while newer filing references 2025-2026 events (September 2025 through March 2026).
- Comparison is between Q3 2025 filing (period ended September 30, 2025) and Q1 2026 filing (period ended March 31, 2026), representing different fiscal periods.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-040 buys · 8 sells ($939748) — 8 selling insiders
Most recent open-market transaction: 2026-06-04. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NVCR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
NVCR had 11,796,425 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
NVCR had 10.1% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.48 days to cover at the same settlement.
- Reported short interest (shares) 11,796,425
- Short interest (% of shares outstanding) 10.1%
- Prior settlement (shares) 10,788,851
- Reported change 9.34%
- Days to cover (reported) 11.48
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic (MDT)
- Boston Scientific (BSX)
- Varian Medical Systems (Siemens Healthineers)
- Elekta (EKTA-B.ST)
- Accuray (ARAY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NVCR vs…
NOVOCURE LTD is found in…
Frequently asked questions
What does NOVOCURE LTD (NVCR) do?
Novocure is an oncology company that develops and commercializes Tumor Treating Fields (TTFields), a non-invasive cancer therapy that uses electric fields to disrupt solid tumor cell division. The company's primary focus is the treatment of aggressive solid tumors, such as glioblastoma (GBM). Its technology is delivered through wearable devices that patients use in their daily lives.
What sector is NOVOCURE LTD (NVCR) in?
NOVOCURE LTD (NVCR) is classified in the Health Care sector. Its industry is medical devices - oncology. It trades on NASDAQ.
Who are NOVOCURE LTD's (NVCR) competitors?
Notable peers of NOVOCURE LTD (NVCR) include Medtronic, Boston Scientific, Varian Medical Systems (Siemens Healthineers), Elekta (EKTA-B.ST) and Accuray. This peer set is informational only — not financial advice.
Is NOVOCURE LTD (NVCR) overbought or oversold right now?
NOVOCURE LTD (NVCR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 30, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NVCR come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.